What is BioCryst Pharmaceuticals's net income?

BioCryst Pharmaceuticals (BCRX) reported net income of -$721.81M in Q1 2026.

How has BioCryst Pharmaceuticals's net income changed year-over-year?

BioCryst Pharmaceuticals's net income decreased by 2255762.5% year-over-year, from $32K to -$721.81M.

What is the long-term trend for BioCryst Pharmaceuticals's net income?

Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's net income has grown at a 9.4% compound annual growth rate (CAGR), from -$184.06M to $263.86M.

What does net income mean?

Net income as the starting point for the indirect method operating cash flow reconciliation.

BioCryst Pharmaceuticals BCRX Net Income

Net Income at other companies

Ionis PharmaceuticalsIONS

-$92.53M+37.0%

Ultragenyx PharmaceuticalRARE

-$185M-22.5%

BridgeBio PharmaBBIO

-$166.56M+1.8%

Arrowhead ResearchARWR

-$137.57M-137%

Agios PharmaceuticalsAGIO

-$99.11M-11.0%

ALN

Alnylam PharmaceuticalsALNY

$205.99M+1,229%

Segments

By segment

See full

Reportable Segment-$721.81M-2,255,763%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's net income?: BioCryst Pharmaceuticals (BCRX) reported net income of -$721.81M in Q1 2026.
How has BioCryst Pharmaceuticals's net income changed year-over-year?: BioCryst Pharmaceuticals's net income decreased by 2255762.5% year-over-year, from $32K to -$721.81M.
What is the long-term trend for BioCryst Pharmaceuticals's net income?: Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's net income has grown at a 9.4% compound annual growth rate (CAGR), from -$184.06M to $263.86M.
What does net income mean?: Net income as the starting point for the indirect method operating cash flow reconciliation.